176 related articles for article (PubMed ID: 34569009)
1. Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview.
Schultze-Mosgau MH; Ploeger BA; Frei M; Höchel J; Rottmann A
Clin Pharmacokinet; 2022 Jan; 61(1):1-16. PubMed ID: 34569009
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women.
Liu H; Jiang J; Chen Z; Zhang Y; Li J; Hoechel J; Rohde B; Zimmermann T; Schultze-Mosgau MH
Clin Pharmacol Drug Dev; 2021 May; 10(5):486-493. PubMed ID: 32716091
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Chattopadhyay N; Kanacher T; Casjens M; Frechen S; Ligges S; Zimmermann T; Rottmann A; Ploeger B; Höchel J; Schultze-Mosgau MH
Br J Clin Pharmacol; 2018 Dec; 84(12):2857-2866. PubMed ID: 30171692
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
.
Schultze-Mosgau MH; Schuett B; Hafner FT; Zollmann F; Kaiser A; Hoechel J; Rohde B
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):16-24. PubMed ID: 27841155
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
Schultze-Mosgau MH; Höchel J; Prien O; Zimmermann T; Brooks A; Bush J; Rottmann A
Clin Pharmacokinet; 2018 Aug; 57(8):1001-1015. PubMed ID: 29330782
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.
Schultze-Mosgau MH; Lasseter KC; Marbury T; Loewen S; Riecke K
J Clin Pharmacol; 2020 Aug; 60(8):1030-1038. PubMed ID: 32227643
[TBL] [Abstract][Full Text] [Related]
10. Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women.
Schultze-Mosgau MH; Kaiser A; Zollmann FS
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):675-680. PubMed ID: 33021044
[TBL] [Abstract][Full Text] [Related]
11. Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women.
Schütt B; Schultze-Mosgau MH; Draeger C; Chang X; Löwen S; Kaiser A; Rohde B
J Clin Pharmacol; 2018 Feb; 58(2):228-239. PubMed ID: 28940451
[TBL] [Abstract][Full Text] [Related]
12. Vilaprisan for treating uterine fibroids.
Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
[TBL] [Abstract][Full Text] [Related]
13. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial.
Schultze-Mosgau MH; Matsuki S; Okumura K; Kaneko M
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):49-56. PubMed ID: 34635989
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K; Heikinheimo O; Zatik J; Poka R; Rechberger T; Hudecek R; Petersdorf K; Ramirez F; Faustmann T; Groettrup-Wolfers E; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():7-14. PubMed ID: 32559602
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.
Sutter G; Frei M; Schultze-Mosgau MH; Petersdorf K; Seitz C; Ploeger BA
Br J Clin Pharmacol; 2022 Feb; 88(2):734-741. PubMed ID: 34327754
[TBL] [Abstract][Full Text] [Related]
16. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.
Möller C; Bone W; Cleve A; Klar U; Rotgeri A; Rottmann A; Schultze-Mosgau MH; Wagenfeld A; Schwede W
ChemMedChem; 2018 Nov; 13(21):2271-2280. PubMed ID: 30407750
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
Seitz C; Bumbuliene Ž; Costa AR; Heikinheimo O; Heweker A; Hudeček R; Jacquemyn Y; Melis GB; Parashar P; Rechberger T; Sánchez AC; van Aken B; Zatik J; Gemzell-Danielsson K
Contemp Clin Trials; 2017 Apr; 55():56-62. PubMed ID: 28185997
[TBL] [Abstract][Full Text] [Related]
19. Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?
Ciebiera M; Vitale SG; Ferrero S; Vilos GA; Barra F; Caruso S; Laganà AS; Sierant A; Cianci A; Jakiel G
Curr Pharm Des; 2020; 26(3):300-309. PubMed ID: 31985366
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Gandhi Y; Eley T; Fura A; Li W; Bertz RJ; Garimella T
Clin Pharmacokinet; 2018 Aug; 57(8):911-928. PubMed ID: 29353349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
